Sanofi Releases P-III (HERCULES) Data of Tolebrutinib (BTKi) for non-relapsing Secondary Progressive MS (nrSPMS)
Shots:
- Sanofi reported the data from the P-III (HERCULES) trial assessing the efficacy and safety of tolebrutinib (oral) vs PBO in patients with nrSPMS
- The study met its 1EP by delaying the onset of confirmed disability progression (CDP) in nrSPMS patients. The 1EP outcome was defined as a 6-mons. CDP, indicated by an increase of ≥1.0 point from the baseline EDSS score when it was ≤5.0 or an increase of ≥0.5 point when it was >5.0
- The company expects to present the data from HERCULES and GEMINI 1 and 2 evaluating tolebrutinib at the ECTRIMS on 20th Sep
Ref: Sanofi | Image: Sanofi
Related News: Sanofi Pauses Patient Enrollment in P-III Studies of Tolebrutinib for the Treatment of Multiple Sclerosis and Myasthenia Gravis in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
